TC BioPharm Limited Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS

INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 4. INTANGIBLE ASSETS

The Company’s intangible assets consist of the following:

SCHEDULE OF INTANGIBLE ASSETS

	Software		Patents and Licenses		Total
Cost
At December 31, 2023		49,613		810,993		860,606
Intangible assets, Beginning		49,613		810,993		860,606
Additions		-		5,618		5,618
At March 31, 2024		49,613		816,611		866,224
Intangible assets, Ending		49,613		816,611		866,224

Amortization
At December 31, 2023		49,613		195,823		245,436
Amortization expense		-		12,276		12,276
At March 31, 2024		49,613		208,099		257,712

Net book value
At March 31, 2024	£	-	£	608,512	£	608,512

At December 31, 2023	£	-	£	615,170	£	615,170

Amortization expense on these assets for the three months ended March 31, 2024 and 2023, was £12,276 and £11,815, respectively, and is included in research and development expenses in the accompanying unaudited condensed consolidated statements of operations.